Clinical and laboratory characteristics of clozapine treated schizophrenia patients referred to a national immunodeficiency clinic reveals a B-cell signature resembling CVID

M.J. Ponsford; R. Steven; K. Bramhall; M Burgess; S Wijetilleka; E. Carne; F McGuire; C. Price; M. Moody; S Zouwail; T Tahir; D. Farewell; T. El-Shanawany; S. Jolles

doi:10.1101/19007815

Abstract

Purpose An association between antibody deficiency and clozapine use in individuals with Schizophrenia has recently been reported. We hypothesized that if clozapine-associated hypogammaglobulinaemia was clinically relevant this would manifest in referral patterns.

Methods Retrospective case note review of patients referred and assessed by Immunology Centre for Wales (ICW) between January 2005 and July 2018 with extraction of clinical and immunologic features for individuals with diagnosis of schizophrenia-like illness.

Results 1791 adult patients were assessed at ICW during this period; 23 patients had a psychiatric diagnosis of schizophrenia or schizo-affective disorder. Principal indications for referral were findings of low calculated globulin and immunoglobulins. Clozapine was the single most commonly prescribed antipsychotic (17/23), disproportionately increased relative to reported use in the general schizophrenia population (OR 6.48, 95% CI: 1.79 to 23.5). Clozapine therapy was noted in 6/7 (86%) of patients subsequently requiring immunoglobulin replacement therapy (IgRT). Marked reduction of class-switched memory B-cells (CSMB) and plasmablasts were observed in clozapine-treated individuals relative to healthy age-matched controls. Clozapine duration is associated with CSMB decline. One patient discontinued clozapine, with gradual recovery of IgG levels without use of IgRT.

Conclusion Our findings are consistent with enrichment of clozapine-treatment within schizophrenic individuals referred for ICW assessment over the last 13 years. These individuals displayed clinical patterns closely resembling the primary immunodeficiency CVID, however appears reversible upon drug cessation. This has diagnostic, monitoring and treatment implications for psychiatry and immunology teams and directs prospective studies to address causality and the wider implications for this patient group.

Competing Interest Statement

MP is supported by a Welsh Clinical Academic Training Fellowship and Wellcome Trust Institutional Strategic Support Fund (ISSF) grant. SJ has received support from CSL Behring, Shire, LFB, Biotest, Binding Site, Sanofi, GSK, UCB Pharma, Grifols, BPL SOBI, Weatherden, Zarodex and Octapharma for projects, advisory boards, meetings, studies, speaker, and clinical trials. TE has received educational support, project support, advisory board fees, speaker fees and/or clinical trial support from Biotest, CSL, LFB, Mylan, Novartis, Shire and Werfen. CP has received support to attend educational meetings from CSL Behring and ALK. The remaining authors have no relevant conflicts of interest to declare.

Funding Statement

Author Declarations

All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Not Applicable

Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.

Not Applicable

I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.

Not Applicable

Footnotes

DF provided support for statistical analysis.
SW, EMC, FMG, CP, SZ, TT, and TES contributed to clinical record extraction and/or interpretation of data. All authors critically reviewed and approved the final version.

Data Availability

Supplementary information also uploaded

Abbreviations

CSMB: Class switched memory B-cells
CVID: Common variable immunodeficiency
EAE: Experimental autoimmune encephalitis
IgRT: Immunoglobulin replacement therapy
22q11ds: 22q11 deletion syndrome (also known as DiGeorge)
TRS: Treatment resistant schizophrenia

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.